← Browse by Condition
Medical Condition

pure red cell aplasia

Total Trials
2
Recruiting Now
2
Trial Phases
Phase 2

ClinicalMetric tracks all active clinical trials for pure red cell aplasia sourced from ClinicalTrials.gov. Research in this area spans early-phase safety investigations through large Phase 3 confirmatory trials, conducted by NIH-funded academic centers, independent investigators, and pharmaceutical sponsors worldwide. Each listing is updated daily as new studies open enrollment and existing ones reach capacity or complete follow-up.

Trial listings include the NCT identifier, current recruitment status, phase classification, primary and secondary endpoints, estimated enrollment size, participating countries, and direct links to the full protocol on ClinicalTrials.gov. Eligibility criteria — including age range, disease stage, and prior treatment requirements — are documented for every study to help patients and clinicians assess suitability before contacting a trial site.

Frequently Asked Questions — pure red cell aplasia Clinical Trials

How many clinical trials are currently recruiting for pure red cell aplasia?
ClinicalMetric currently tracks 2 actively recruiting clinical trials for pure red cell aplasia, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 2. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for pure red cell aplasia?
pure red cell aplasia research spans Phase 2 (1 trial). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a pure red cell aplasia clinical trial?
Eligibility criteria for pure red cell aplasia trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Trial Phases
Phase 2
1
Top Sponsors
University of Calgary 1 trial
UK Kidney Association 1 trial

Recruiting Clinical Trials

NCT03214354 Phase 2
Recruiting
Nonmyeloablative Stem Cell Transplant in Children With Sickle Cell Disease and a Major ABO-Incompatible Matched Sibling Donor
Enrollment
12 pts
Location
Canada
Sponsor
University of Calgary
View Trial →
NCT06065852
Recruiting
National Registry of Rare Kidney Diseases
Enrollment
35,000 pts
Location
United Kingdom
Sponsor
UK Kidney Association
View Trial →

Related Conditions

sickle cell disease (1) stem cell transplant complications (1) red blood cell disorder (1) adenine phosphoribosyltransferase deficiency (1) ah amyloidosis (1) ahl amyloidosis (1) al amyloidosis (1) alport syndrome (1) atypical hemolytic uremic syndrome (1) autoimmune distal renal tubular acidosis (1) autosomal recessive proximal renal tubular acidosis (1) autosomal recessive distal renal tubular acidosis (1)
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology